Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK-SPEED: Human Urinary Kallidinogenase in Acute Ischemic Stroke
NCT06132880Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Dec 2023
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Randomised, open-label trial of human urinary kallidinogenase + Shuxuening injection in ischemic stroke (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Proportion of patients with modified Rankin Scale 0-2 at 90 days. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
human urinary kallidinogenase + Shuxuening injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06132880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132880.